白藜蘆醇是一種天然植物多酚，它可以影響多種調控途徑去影響癌症細胞，例如透過細胞凋亡的機制促使癌症細胞死亡，或者透過抑制癌細胞的增生。但對於白藜蘆醇是否可以降低鼻咽癌細胞中腫瘤抑制基因的異常甲基化以及是否可以降低鼻咽癌細胞移動能力，我們還不是非常地清楚。在此我們先將四種鼻咽癌細胞株TW-04、TW-076、HK-1和C666-1處理不同濃度的白藜蘆醇後發現，當濃度超過100 μM時，會有明顯的細胞毒殺現象；但同樣情況下對正常鼻咽細胞NP-69並沒有毒殺現象。接著，我們透過Methylation-specific PCR來分析RASSF1A、DAPK1、RARβ2和MGMT這四種腫瘤抑制基因在鼻咽癌細胞株中異常甲基化的情形，並比較施予白藜蘆醇於鼻咽癌細胞株對基因甲基化的影響。結果發現這四個基因在鼻咽癌細胞株皆具有異常甲基化的情形，而在給予白藜蘆醇後，發現對不同鼻咽癌細胞株有不同去甲基化的影響。而透過Boyden’s chamber migration assay以及傷口癒合試驗(wound-healing assay)，並發現當TW-04、TW-076、HK-1和C666-1鼻咽癌細胞株給予50 μM白藜蘆醇後，其細胞移動能力分別下降37%、78%、62.5% 以及86%。我們的結果顯示，白藜蘆醇可以降低異常基因甲基化的程度，且可以抑制鼻咽癌細胞株的移動能力。以上結果，證實白藜蘆醇是具有潛力成為一個治療鼻咽癌的藥物，並在抑制鼻咽癌轉移有不錯的結果。

Resveratrol, a naturally dietary compound, has been reported that it affected
many pathways to cause apoptosis or to inhibit cell proliferation in various cancers. But we were not sure about the effects of resveratrol on aberrant hypermethylation levels of tumor suppressor genes and cell motility in nasopharyngeal carcinoma (NPC). First, we treated four NPC cell lines, TW-04, TW-076, HK-1 and C666-1 with various concentrations of resveratrol. This resulted in significant decrease in cell viability when the concentration of resveratrol was equal or higher than 100 μM. On the other hand, resveratrol treatment didn’t cause cell death in normal cells, NP-69. Next, we studied RASSF1A, DAPK, RARβ2 and MGMT methylation statuses in NPC cell lines by methylation-specific PCR (MSP), and compared them with those in resveratrol treated NPC cell lines. The aberrant hypermethylation of RASSF1A, DAPK, RARβ2 and MGMT was detected in all NPC cell lines (TW-04, TW-076, HK-1 and C666-1). At least one of tumor suppressor genes could be partially demethylated after treatment with resveratrol. Four of these genes could be demethylated at different levels in NPC cell lines upon treatment of resveratrol. Moreover, we treated resveratrol to NPC cell lines and analyzed with Boyden’s chamber migration assay and wound-healing assay. We found that the cell migration abilities of resveratrol-treated TW-04, TW-076, HK-1 and C666-1 cells were decreased 37%, 78%, 62.5% and 86%, respectively. Our results implicated that resveratrol treatments reduced tumor suppressor genes’ aberrant hypermethylation levels in NPC, and might affect the regulation of cell motility in NPC. To sum up, our findings pointed out that resveratrol had potential to be developed as an anti-cancer drug and to prevent NPC metastasis.

American Cancer Society(ACC). 2013. Nasopharyngeal cancer. American Cancer Society p.28-29.
American Joint Committee on Cnacer(AJCC). 2010. In AJCC cancer staging Manual, 7th ed. New York Springer p.41-49.
Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitely R, Yamanishi K. 2007. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press.
Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat clin pract oncol 2 suppl 1:S4-11.
Burrows JM, Burrows SR, Poulsen LM, Sculley TB, Moss DJ, Khanna R. 1996. Unusually high frequency of Epstein-Barr virus genetic variants Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol 70(4):2490-6.
Cao Y, Miao XP, Huang MY, Deng L, Hu LF, Ernberg I, Zeng YX, Lin DX, Shao JY. 2006. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 6(6):167.
Carmona FJ, Azuara D, Berenguer Llergo A, Fernandez AF, Biondo S, de Oca J, Rodriguez-Moranta F, Salazar R, Villanueva A, Fraga MF, Guardiola J, Capella G, Esteller M, Moreno V. 2013. DNA methylation biomarkers for non-invasive diagnostic of Colorectal Cancer. Cancer Prev Res (Phila). 6(7):656-65.
Chambon P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J 10(9):940–54.
Chan AT, Teo PM, Leung TW, Johnson PJ. 1998. The role of chemotherapy in themanagement of nasopharyngeal carcinoma. Cancer 82(6):1003-12.
Chan SL, Ma BB. 2012. Novel systemic therapeutic for nasopharyngeal carcinoma. Expert opin ther targets 16 Suppl 1:S63-8.
Cheah SK, Lau FN, Yusof MM, Phua VC. 2013. Treatment outcome with brachytherapy for recurrent nasopharyngeal carcinoma. Asain pac j cancer prev 14(11):6513-8.
Chen HJ, Hsu LS, Shia YT, Lin MW, Lin CM. 2012. The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem Pharmacol 84(9):1143-53.
Cheng SH, Jian JJ, Tsai SY, Yen KL, Chu NM, Chan KY, Tan TD, Cheng JC, Leu SY, Hsieh CY, Huang AT. 2000. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 48(5):1323-30.
Chen X, He B. 1998. Oxygen free radical scavenging activity and anti-lipid peroxidation of tea polyphenol. Zhong Yao Cai 21(3):141-4.
Cho EY, Hildesheim A, Chen CJ, Hsu MM, Chen IH, Mittl BF, Levine PH, Liu MY, Chen JY, Brinton LA, Cheng YJ, Yang CS. 2003. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev 12(10):1100-4.
Clark SJ, Harrison J, Molloy PL. 1997. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 195(1):67-71.
Cohen O, Kimchi A. 2001. DAP-Kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ 8(1):6–15.
Comb M, Goodman HM. 1990. CpG methylation inhibits proenkephalin gene expression and binding of the reanscription factor AP-2. Nucleic Acids Res 18(13):3975-82.
Cullberg KB, Olholm J, Paulsen SK, Foldager CB, Lind M, Richelsen B, Pedersen SB. 2013. Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro. Eur J Pharm Sci 49(2):251-7.
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. 2007. Cancer incidence in five continents. IRAC 9:442-445.
Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. 2005. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20(2):645–63.
Danam RP, Howell SR, Brent TP, Harris LC. 2005. Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol Cancer Ther 4(1):61-9.
Ehrlich M, Wang RY. 1981. 5-Methylcytosine in eukaryotic DNA. Science 212(4501):1350-7.
Esteller M, Corn PG, Baylin SB, Herman JG. 2001. A gene hypermethylation profile of human cancer. Cancer Res 61(8):3225-9.
Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R. 2009. Inactivation of RASSF1A, RARβ2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther 8(5):444–51.
Fremont L. 2000. Biological effects of resveratrol. Life Sci 66(8)663-673.
Garvin S, Ollinger K, Dabrosin C. 2006. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231(1): 113–22.
Hachana M, Trimeche M, Ziadi S, Amara K, Korbi S. 2009. Evidence for a role of the Simian virus 40 in human breast carcinomas. Breast Cancer Res Treat 113(1):43-58.
Hau PM, Tsang CM, Yip YL, Huen MS, Tsao SW. 2011. Id1 interacts and stabilizes the Epstein-Barr virus latent membrane protein 1(LMP1) in nasopharyngeal epithelial cells. PLoS One 6(6):e21176.
He W, Li X, Xu S, Ai J, Gong Y, Gregg JL, Guan R, Qiu W, Xin D, Gingrich JR, Guo Y, Chang G. 2013. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun 435(4):526-32.
Henle W, Henle G, Ho HC, Burtin P, Cachin Y, Clifford P, de Schryver A, de-Thé G, Diehl V, Klein G. 1970. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 44(1):225-31.
Henle G, Henle W. 1976. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17(1):1-7.
Herman JG, Larif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91(21):9700-4.
Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, Mack SJ, Chen IH, Hsu MM, Yang CS, Brinton LA, Levine PH, Erlich HA. 2002. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94(23):1780-9.
Ho JH. 1978. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 4(3-4):182-98.
Holloday R, Pugh JE. 1975. DNA modification mechanisms and gene activity during development. Science 187(4173):226-32.
Hsu MM, Tu SM. 1983. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 52(2):362-8.
Huang DP, Ho JH, Henle W, Henle G. 1974. Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies. Int J Cancer 14(5):580-8.
Huang TT, Lin HC, Chen CC, Wei CF, Wu TS, Liu FG, Hai HC. 2011. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways. J Cell Physiol 226(3):720-8.
Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP. 2003. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog 38(4):170-178.
Iguchi-Ariga SM, Schaffner W. 1989. CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 3(5):612-9.
Imai S, Nishikawa J, Takada K. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72(5): 4371–8.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218-20.
Jian JJ, Cheng SH, Tsai SY, Yen KC, Chu NM, Chan KY, Tan TD, Cheng JC, Lin YC, Leu SY, Hsieh CI, Tsou MH, Lin CY, Huang AT. 2002. Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 53(2): 344-52.
Jiang WH, Zhao SP, Yin ZH, Li F, Chen ZH, Xiao JY. 2005. Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue. Ai Zheng 24(7):796-800.
Joseph Kwong, Kwok-Wai Lo, Fa-Fai To, Peter ML Teo, Philip J Johnson, Dolly Poon Huang. 2002. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8(1):131-137.
Kutter J, Ozsahin M, Monnier P, Stupp R. 2005. Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol 262(1):1-7.
Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. 2002. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8(1):131-7.
Kwong J, Lo KW, Chow LS, To KF, Choy Kw, Chan FL, Mok SC, Huang DP. 2005. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 7(1):67-74.
Li HP, Leu YW, Chang YS. 2005. Epigenetic changes in virus-associated human cancers. Cell Res 15(4):262-71.
Li W, Ma J, Ma Q, Li B, Han L, Liu J, Xu Q, Duan W, Yu S, Wang F, Wu E. 2013. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NFκB pathway. Curr Med Chem 20(33):4185-94.
Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazzé S, Bruzzi P, Gatta G, Molinari R. 2003. Cancer of the nasopharynx. Crit Rev Oncol Hematol 45(2):199-213.
Lien EJ, Ren SJ, Bui HUH, Wang RB. 1999. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med 26(2):285-94.
Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. 2003. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21(4):631-7.
Lin X, Dai X, Wu B. 2009. Study of 5-Aza-CdR on transcription regulation of RASSF1A gene in the BIU87 cell line. Urol Int 82(1):108-12.
Lin Z, Wu VW, Lin J, Feng H, Chen L. 2011. A longitudinal study on the radiation-induced thyroid gland changes after external beam radiotherapy of nasopharyngeal. Thyroid 21(1):19-23.
Liu Z, Zhang L, Ding F, Li J, Guo M, Li W, Wang Y, Yu Z, Zhan Q, Wu M, Liu Z. 2005. 5-Aza-2’-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett 230(2):271-83.
Lo KW, Huang DP. 2002. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 12(6):451-462.
Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, chow LS, Teo PM, Johnson PJ, Huang DP. 2001. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61(10):3877–81.
Lo KW, To KF, Huang DP. 2004. Focus on nasopharyngeal carcinoma. Cancer cell 5(5):423-8.
Ning JP, Yu MC, Wang QS, Henderson BE. 1990. Consumption of salted fish and other risk factors for nasopharyngeal carcinoma (NPC) in Tianjin, a low-risk region for NPC in the People’s Republic of China. J Natl Cancer Inst 82(4):291-6.
Niture SK, Velu CS, Smith QR, Bhat GJ, Srivengopal KS. 2007. Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. Carcinogenesis 28(2):372-89.
Nonoyama M, Huang CH, Pagano JS, Kelein G, Singh S. 1973. DNA of Epstein-Barr virus detected in tissue of Burkitt’s lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci USA 70(11):3265-8.
Ouyang PY, Su Z, Mao YP, Liang XX, Liu Q, Deng W, Xie FY. 2013. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 22(12):2285-94.
Pandey Pr, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, Wakabayashi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Fujioka T, Tanji S, Mo YY, Cao D, Wilber AC, Watabe K. 2011. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 130(2):387-98.
Papoutsis AJ, Borg JL, Selmin OI, Romagnolo DF. 2012. BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. J Nutr Biochem 23(10):1324-32.
Poussier B, Cordova AC, Becquemin JP, Sumpio BE. 2005. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg 42(6):1190–7.
Raab-Traub N, and Flynn K. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47(6)883-889.
Raab-Traub N. 2002. Epstein-barr virus in the pathogenesis of NPC. Semin Cancer Biol 12(6):431-441.
Razin A, Riggs AD. 1980. DNA methylation gene function. Science 210(4470):604-10.
Ross JA, Kasum CM. 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22(1):19-34.
Schroder G, Brown JW, Schroder J. 1988. Molecular analysis of resveratrol synthase. cDNA, genomic clones and relationship with chalcone synthase. Eur J Biochem 172(1):161-9.
Simon P. 2003. Cancer cell culture: methods and protocols. Human Press 271-82.
Seo SY, Kim EO, Jang KL. 2008. Epstein-Bar virus latent membrane protein 1 suppresses the growth-inhibitory effect of retinoic acid by inhibiting retinoic acid receptor-2β expression via DNA methylation. Cancer Lett 270(1):66–76.
Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP, Ramkumar V. 2012. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PloS One 7(12):e51655.
Shiraishi A, Sakumi K, Sekiguchi M. 2000. Increased susceptibility to chemotherapeutic alkyling agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 21(10):1879-83.
Sobin LH, Gospodarowicz MK, Wittekind C. 2009. TNM classifyion of malignant tumours, 7th ed. Wiley-Liss. UICC.
Soleas GJ, Diamandis EP, Goldberg DM. 1997. Resveratrol: a molecule whose time has come? And Gone? Clin Biochem 30(2):91-113.
Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273(34):21875-82.
Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. 2000. Hypermethylation of the death associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92(18):1511-6.
Tao Q, Chan AT. 2007. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9(12):1-24.
Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, Tsao SW, Tse KP, Yu JS, Chang YS. 2006. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 66(24):11668-76.
Teng SD. 2013. 口腔癌治療成果.和信治癌中心醫院. http://www.kfsyscc.org/cancer/head-neck-and-nasopharyngeal-carcinoma/therapy/outcome/
Thompson CM, Grafström RC. 2009. Commentary: mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53 doi:10.1186/1476-069X-8-53.
Ward MH, Pan WH, Cheng YJ, Li FH, Brinton LA, Chen CJ, Hsu MM, Chen IH, Levine PH, Yang CS, Hildesheim A. 2000. Dietary exposure to nitrite nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. Int J Cancer 86(5):603-9.
Weizhu Zhu, Wenyi Qin, Ke Zhang, George E. Rottinghaus, Yin-Chieh Chen, Beth Kliethermes, Edwar R. Sauter. 2012. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 64(3):393-400.
Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX, Zeng MS, Jia WH. 2012. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst 104(18):1396-410.
Xu NR, Liu CX, Zheng SB, Li HL, Xu YW, Xu K. 2009. Reversion transcriptional expression of DAPK in bladder cancer T24 cells 5-aza-2’-deoxycytidine. Nan Fang Yi Ke Da Xue Xue Bao 29(9):1882-6.
Yu MC, Nichols PW, Zou XN, Estes J, Henderson BE. 1989a. Induction of malignant nasal cavity tumours in Wistar rats fed Chinese salted fish. Br J Cancer 60(2):198-201.
Yu MC, Huang TB, Henderson BE. 1989b. Diet and nasopharyngeal carcinoma: a case control study in GuangZhou, China. Int J Cancer 43(6)1077-82.
Yu MC, Yuan JM. 2002. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12(6):421-9.
Zheng X, Yan L, Nilsson B, Eklund G, Drettner B. 1994a. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol 33(8):867-72.
Zheng YM, Tuppin P, Hubert A, Jeannel D, Pan YJ, Zeng Y, de Thé G. 1994b. Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China. Br J Cancer 69(3):508-14.
衛生福利部國民健康署癌症登記線上互動查詢系統. 2009 https://cris.hpa.gov.tw/pagepub/Home.aspx